Investigation of Antidepressant Efficacy of Oral Ketamine Treatment
- Registration Number
- NCT02992496
- Lead Sponsor
- Medical University of Vienna
- Brief Summary
The purpose of this double-blind, controlled, randomized study is to investigate the antidepressant efficacy of oral ketamine treatment in patients suffering from a major depressive episode.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Diagnosis of a major depressive episode in the scope of a major depressive or bipolar disorder supported by a Structured Clinical Interview for DSM-IV-TR (SCID)
- Hamilton depression rating scale score ≥ 19
- Willingness and competence to sign the informed consent form
- Stable psychopharmacological treatment for 10 days (except benzodiazepines)
Exclusion Criteria
- Initiation of a new antidepressant or mood stabilizing treatment (pharmacological, physical or psychotherapeutic) with adequate dosage (as defined by the minimum recommended dose in the respective prescribing information) within 4 weeks prior to inclusion
- Prior use of ketamine
- Pregnancy/Breast feeding
- Instable arterial hypertension >170/110mmHg
- Hepatic dysfunction
- Hyperthyreosis
- History of glaucoma
- Neurodegenerative disorders
- Any unstable medical illness
- History of substance abuse within the past 12 months
- History of psychosis
- Failure to comply with the study protocol or to follow the instructions of the investigating team
- Current treatment with one of the following drugs: clopidogrel, carbamazepine, valproate, barbiturates, memantine, modafinil, disulfiram, amiodarone, ranolazine, phenytoin, verapamil, fibrates, antiretroviral agents, antimicrobial chemotherapeutics, azole antifungals, glucocorticoids, cyclosporine, valeriana/garlic/grapefruit preparations, St. John's wort.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control group Midazolam Hydrochloride Each patient will undergo six treatment sessions with 0.03mg/kg oral midazolam over 2 weeks Ketamine treatment group Ketamine Each patient will undergo six treatment sessions with 1mg/kg oral ketamine over 2 weeks.
- Primary Outcome Measures
Name Time Method Montgomery-Åsberg Depression Rating Scale (MADRS) 1 week
- Secondary Outcome Measures
Name Time Method Hamilton Depression Rating Scale 1 week Clinician Administered Dissociative States Scale (CADSS) 2 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie ketamine's antidepressant effects in major depressive episodes?
How does oral ketamine compare to standard-of-care antidepressants in treating major depressive episodes?
Which biomarkers predict response to ketamine in patients with major depressive episodes?
What are the potential adverse events associated with oral ketamine for depression and how are they managed?
Are there combination therapies involving ketamine that enhance antidepressant efficacy in major depressive disorder?
Trial Locations
- Locations (1)
Department of Psychiatry and Psychotherapy, Medical University of Vienna
🇦🇹Vienna, Austria
Department of Psychiatry and Psychotherapy, Medical University of Vienna🇦🇹Vienna, AustriaRupert Lanzenberger, A/Prof.Contact+43 40400rupert.lanzenberger@meduniwien.ac.atRupert Lanzenberger, A/Prof. MDPrincipal Investigator